FI76090C - Foerfarande foer isolering av foer diagnostiska aendamaol laempligt a-ristomycin och dess derivat med hoeg renhetsgrad fraon orent ristomycin eller rao-ristomycin. - Google Patents

Foerfarande foer isolering av foer diagnostiska aendamaol laempligt a-ristomycin och dess derivat med hoeg renhetsgrad fraon orent ristomycin eller rao-ristomycin. Download PDF

Info

Publication number: FI76090C
Authority: FI; Finland
Prior art keywords: ristomycin; crude; alpha; solution; hydrogen atom
Prior art date: 1982-09-21

Application number

FI833388A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI833388A7 (fi

FI76090B (fi

FI833388A0 (fi

Inventor

Kalman Rak

Zoltan Boda

Rezso Bognar

Ferenc Sztaricskai

Gabriella Zajka

Original Assignee

Reanal Finomvegyszergyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-09-21

Filing date

1983-09-21

Publication date

1988-09-09

1983-09-21 Application filed by Reanal Finomvegyszergyar filed Critical Reanal Finomvegyszergyar

1983-09-21 Publication of FI833388A0 publication Critical patent/FI833388A0/fi

1984-03-22 Publication of FI833388A7 publication Critical patent/FI833388A7/fi

1986-09-22 Priority to FI863825A priority Critical patent/FI75936C/fi

1988-05-31 Publication of FI76090B publication Critical patent/FI76090B/fi

1988-09-09 Application granted granted Critical

1988-09-09 Publication of FI76090C publication Critical patent/FI76090C/fi

Links

BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 title claims description 37
108010081391 Ristocetin Proteins 0.000 title claims description 36
238000000034 method Methods 0.000 title claims description 16
230000008569 process Effects 0.000 title description 5
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 9
239000007864 aqueous solution Substances 0.000 claims description 9
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
238000003556 assay Methods 0.000 claims description 6
-1 aliphatic carboxylic acid nitrile Chemical class 0.000 claims description 5
229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
239000011707 mineral Substances 0.000 claims description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 4
239000000908 ammonium hydroxide Substances 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
229910021653 sulphate ion Inorganic materials 0.000 claims description 4
239000003960 organic solvent Substances 0.000 claims description 3
239000012670 alkaline solution Substances 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
SHZGCJCMOBCMKK-HGVZOGFYSA-N alpha-L-rhamnopyranose Chemical compound C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-HGVZOGFYSA-N 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
238000002955 isolation Methods 0.000 claims description 2
238000009472 formulation Methods 0.000 claims 2
239000000243 solution Substances 0.000 description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
238000002474 experimental method Methods 0.000 description 14
239000003153 chemical reaction reagent Substances 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
210000001772 blood platelet Anatomy 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000003242 anti bacterial agent Substances 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
239000013543 active substance Substances 0.000 description 8
239000012153 distilled water Substances 0.000 description 8
239000000047 product Substances 0.000 description 8
229950004257 ristocetin Drugs 0.000 description 8
238000012360 testing method Methods 0.000 description 8
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
229940088710 antibiotic agent Drugs 0.000 description 6
239000002585 base Substances 0.000 description 6
238000004220 aggregation Methods 0.000 description 5
230000002776 aggregation Effects 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
238000000354 decomposition reaction Methods 0.000 description 5
VUOPFFVAZTUEGW-SRXUPNLNSA-N 32p08cbb99 Chemical compound C=1C([C@@H]2C(=O)N[C@@H]([C@@H](C3=CC=C(C=C3)OC=3C=C4C=C(C=3O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@@H]([C@H](O)[C@@H](O)[C@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@H]([C@H](O)[C@H](O)CO3)O)OC3=CC=C(C=C3)[C@@H](O)[C@@H]3C(=O)N[C@@H](C=5C=C(C(=C(O)C=5)C)OC=5C(O)=CC=C(C=5)[C@@H](N)C(=O)N3)C(=O)N[C@H]4C(=O)N2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)C(=O)N[C@@H](C2=CC(O)=C3)C(=O)OC)=CC=C(O)C=1C2=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O VUOPFFVAZTUEGW-SRXUPNLNSA-N 0.000 description 4
235000011114 ammonium hydroxide Nutrition 0.000 description 4
230000008859 change Effects 0.000 description 4
239000012043 crude product Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000031700 light absorption Effects 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
108010062729 ristocetin A Proteins 0.000 description 4
108010017384 Blood Proteins Proteins 0.000 description 3
102000004506 Blood Proteins Human genes 0.000 description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
208000031220 Hemophilia Diseases 0.000 description 3
208000009292 Hemophilia A Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000001110 calcium chloride Substances 0.000 description 3
229910001628 calcium chloride Inorganic materials 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
230000006920 protein precipitation Effects 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
108010047303 von Willebrand Factor Proteins 0.000 description 3
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
230000004931 aggregating effect Effects 0.000 description 2
239000003513 alkali Substances 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
235000012736 patent blue V Nutrition 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
VJOACURQAUWHNH-ZETCQYMHSA-N (2s)-2-anilino-3,3-dihydroxypropanoic acid Chemical group OC(O)[C@@H](C(O)=O)NC1=CC=CC=C1 VJOACURQAUWHNH-ZETCQYMHSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
UEUIKXVPXLWUDU-UHFFFAOYSA-N 4-diazoniobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C([N+]#N)C=C1 UEUIKXVPXLWUDU-UHFFFAOYSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
241001430311 Amycolatopsis lurida Species 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010015899 Glycopeptides Proteins 0.000 description 1
102000002068 Glycopeptides Human genes 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
239000012491 analyte Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940124350 antibacterial drug Drugs 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
OSOHBQZPFDDOMK-UHFFFAOYSA-N azane;propan-2-one Chemical compound N.CC(C)=O OSOHBQZPFDDOMK-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
SAKUKAQFBMDKGX-UHFFFAOYSA-N butan-1-ol;2-pyridin-2-ylacetic acid;hydrate Chemical compound O.CCCCO.OC(=O)CC1=CC=CC=N1 SAKUKAQFBMDKGX-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000007710 freezing Methods 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000005286 illumination Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
HFWWEMPLBCKNNM-UHFFFAOYSA-N n-[bis(hydroxyamino)methyl]hydroxylamine Chemical compound ONC(NO)NO HFWWEMPLBCKNNM-UHFFFAOYSA-N 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

FI833388A 1982-09-21 1983-09-21 Foerfarande foer isolering av foer diagnostiska aendamaol laempligt a-ristomycin och dess derivat med hoeg renhetsgrad fraon orent ristomycin eller rao-ristomycin. FI76090C (fi)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
FI863825A FI75936C (fi)	1982-09-21	1986-09-22	Reagens foer anvaendning vid trombocytaggregationsprov.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU823020A HU186121B (en)	1982-09-21	1982-09-21	Process for producing a-ristomycin and/or ristomycin derivative of high purity,and reagent for thrombicyte-aggregation tests containing them
HU302082		1982-09-21

Publications (4)

Publication Number	Publication Date
FI833388A0 FI833388A0 (fi)	1983-09-21
FI833388A7 FI833388A7 (fi)	1984-03-22
FI76090B FI76090B (fi)	1988-05-31
FI76090C true FI76090C (fi)	1988-09-09

Family

ID=10962138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI833388A FI76090C (fi)	1982-09-21	1983-09-21	Foerfarande foer isolering av foer diagnostiska aendamaol laempligt a-ristomycin och dess derivat med hoeg renhetsgrad fraon orent ristomycin eller rao-ristomycin.

Country Status (7)

Country	Link
AT (1)	AT381709B (cs)
CS (1)	CS268796B2 (cs)
DD (1)	DD216023A5 (cs)
DE (1)	DE3334170A1 (cs)
FI (1)	FI76090C (cs)
HU (1)	HU186121B (cs)
NO (1)	NO166790C (cs)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0186476A3 (en) *	1984-12-21	1987-10-21	Hemochek Corporation	Diagnostic kit and method for assaying blood components
DE10013377A1 (de)	2000-03-17	2001-09-20	Dade Behring Marburg Gmbh	Induzierte Aggregation und Agglutination von Plättchen

1982
- 1982-09-21 HU HU823020A patent/HU186121B/hu not_active IP Right Cessation
1983
- 1983-09-21 DD DD83255014A patent/DD216023A5/de not_active IP Right Cessation
- 1983-09-21 FI FI833388A patent/FI76090C/fi not_active IP Right Cessation
- 1983-09-21 AT AT0335983A patent/AT381709B/de not_active IP Right Cessation
- 1983-09-21 DE DE19833334170 patent/DE3334170A1/de not_active Withdrawn
- 1983-09-21 NO NO833396A patent/NO166790C/no unknown
- 1983-09-21 CS CS836881A patent/CS268796B2/cs unknown

Also Published As

Publication number	Publication date
DD216023A5 (de)	1984-11-28
AT381709B (de)	1986-11-25
DE3334170A1 (de)	1984-03-22
ATA335983A (de)	1986-04-15
HU186121B (en)	1985-06-28
NO833396L (no)	1984-03-22
NO166790C (no)	1991-09-04
CS268796B2 (en)	1990-04-11
FI833388A7 (fi)	1984-03-22
NO166790B (no)	1991-05-27
FI76090B (fi)	1988-05-31
CS688183A2 (en)	1989-09-12
FI833388A0 (fi)	1983-09-21

Legal Events

Date	Code	Title	Description
2004-08-31	MM	Patent lapsed	Owner name: REANAL FINOMVEGYSZERGYAR

Publication	Publication Date	Title
Gordon et al.	1943	Partition chromatography in the study of protein constituents
FI112116B (fi)	2003-10-31	Menetelmä proteiinin 3-ulotteisen rakenneinformaation määrittämiseksi ja ravintoväliaine
Nozaki et al.	1971	The solubility of amino acids and two glycine peptides in aqueous ethanol and dioxane solutions: establishment of a hydrophobicity scale
Ishizuka et al.	1970	Characterization of gangliosides from fish brain
AU2002210446B2 (en)	2008-03-20	Protein extracted from the intestines of vertebrates, which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport
CHEN et al.	1980	Studies on the metabolites of fluorescein in rabbit and human urine
CN102838623B (zh)	2014-03-05	头孢米诺钠化合物晶体及其制备方法和含有该化合物晶体的无菌粉针
Engstrom et al.	1975	Purification and characterization of roseotoxin B, a toxic cyclodepsipeptide from Trichothecium roseum
FI76090C (fi)	1988-09-09	Foerfarande foer isolering av foer diagnostiska aendamaol laempligt a-ristomycin och dess derivat med hoeg renhetsgrad fraon orent ristomycin eller rao-ristomycin.
CN103804397B (zh)	2015-02-18	一种头孢西丁钠化合物及其制备方法
Hinman et al.	1953	The Isolation and Purification of Amicetin1
FI75173C (fi)	1988-05-09	Foerfarande foer framstaellning av nya cytostatiskt verkande antracyklinderivat.
FI75936C (fi)	1988-08-08	Reagens foer anvaendning vid trombocytaggregationsprov.
KR100243962B1 (ko)	2000-02-01	글리코펩티드, 이의 제조방법 및 이를 함유하는 약제
Chillemi et al.	1990	The role of methylsulfonium compounds in the biosynthesis of N-methylated metabolites in Chondria coerulescens
EP0182851A1 (en)	1986-06-04	PRIMYCIN COMPONENTS AND METHOD FOR SEPARATING THE ANTIBIOTIC COMPLEX.
CN103304597B (zh)	2015-02-25	一种磷酸肌酸钠化合物,其制备方法及其药物组合物及制备方法
Persmark et al.	1992	Ferric iron uptake in Erwinia chrysanthemi mediated by chrysobactin and related catechol-type compounds
BG65587B1 (bg)	2009-01-30	Дифосфатна сол на производно на 4"- заместен-9-деоксо- 9а-аза-9а-хомоеритромицин и фармацевтичния йсъстав
White	1980	Synthesis of L-[3-2H, 18O] glycerol and its incorporation into the 4-methyl-5-hydroxyethyl thiazole moiety of thiamine by Escherichia coli
Spies	1948	Some Derivatives of L-Tryptophan1
CN113219082A (zh)	2021-08-06	一种头孢硫脒及其制剂中的7-aca及类似物杂质的hplc检测方法
Shen et al.	1972	Bioactive carbohydrate derivatives: I. Analogs of the glycopeptide juncture in immunoglobulins
Suzuki et al.	1988	Biological conversion of benzoic acid in Lemna paucicostata 151 and its relation to flower induction
US5663322A (en)	1997-09-02	Diadenosine tetraphosphate tetrasodium salt dodecahydrate crystals and process for preparation